Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA4 | P22748 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 3/20 | 0.34 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | GLP1R | P43220 | 8/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24297327 | 1.00 | CA2 (0.36) | CA2CA12CA1CA4CA9 | |
| SCHEMBL24297162 | 0.91 | ADRB2 (0.38) | CA2CA12CA1CA4CA9 | |
| SCHEMBL24712359 | 0.90 | TSHR (0.33) | CA2CA12CA1CA4CA9 | |
| SCHEMBL24296991 | 0.88 | CRBN (0.33) | CA2CA12CA1CA4CA9 | |
| SCHEMBL24296994 | 0.88 | CRBN (0.33) | CA2CA12CA1CA4CA9 | |
| SCHEMBL24297328 | 0.88 | CRBN (0.33) | CA2CA12CA1CA4CA9 | |
| SCHEMBL24452681 | 0.86 | MEN1 (0.39) | CA2CA12CA1CA4CA9 | |
| SCHEMBL20904578 | 0.86 | CA2 (0.44) | CA2CA12CA1CA4CA9 | |
| SCHEMBL14575431 | 0.86 | CA2 (0.44) | CA2CA12CA1CA4CA9 | |
| SCHEMBL19594069 | 0.86 | CA2 (0.44) | CA2CA12CA1CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220072141-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072141-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | TGM2, QPCT, TGM3 | CA2 1524/4885CA12 1874/4885CA1 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.